Prostatic Neoplasms — First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer
Citation(s)
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 2010112, Given Once Daily by Subcutaneous Administration or by Continuous Intravenous Infusion, in Subjects With Castration-resistant Prostate Cancer